132 related articles for article (PubMed ID: 34942534)
1. Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation.
Yang J; Liao Q; Price M; Moriarity B; Wolf N; Felices M; Miller JS; Geller MA; Bendzick L; Hopps R; Starr TK; O'Connor CH; Tarullo S; Nelson AC; Turley E; Wang J; McCarthy JB
Transl Oncol; 2022 Feb; 16():101318. PubMed ID: 34942534
[TBL] [Abstract][Full Text] [Related]
2. Chondroitin Sulfate Proteoglycan 4 Provides New Treatment Approach to Preventing Peritoneal Dissemination in Ovarian Cancer.
Uno K; Koya Y; Yoshihara M; Iyoshi S; Kitami K; Sugiyama M; Miyamoto E; Mogi K; Fujimoto H; Yamakita Y; Wang X; Nawa A; Kajiyama H
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338902
[TBL] [Abstract][Full Text] [Related]
3. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
[TBL] [Abstract][Full Text] [Related]
4. The transcription factor ZEB1 mediates the progression of epithelial ovarian cancer by promoting the transcription of CircANKRD17.
Cai W; Zhang Q
J Biochem Mol Toxicol; 2022 Aug; 36(8):e23086. PubMed ID: 35521974
[TBL] [Abstract][Full Text] [Related]
5. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
[TBL] [Abstract][Full Text] [Related]
6. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
Nota SPFT; Osei-Hwedieh DO; Drum DL; Wang X; Sabbatino F; Ferrone S; Schwab JH
Front Oncol; 2022; 12():939166. PubMed ID: 36110930
[TBL] [Abstract][Full Text] [Related]
7. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
[TBL] [Abstract][Full Text] [Related]
8. Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration.
Winship A; Van Sinderen M; Heffernan-Marks A; Dimitriadis E
Int J Oncol; 2017 Mar; 50(3):798-804. PubMed ID: 28098860
[TBL] [Abstract][Full Text] [Related]
9. Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells.
Moraya AI; Ali JL; Samadder P; Liang L; Morrison LC; Werbowetski-Ogilvie TE; Ogunsina M; Schweizer F; Arthur G; Nachtigal MW
J Exp Clin Cancer Res; 2017 May; 36(1):67. PubMed ID: 28499442
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells.
Sakata J; Utsumi F; Suzuki S; Niimi K; Yamamoto E; Shibata K; Senga T; Kikkawa F; Kajiyama H
Oncotarget; 2017 Nov; 8(59):99482-99494. PubMed ID: 29245917
[TBL] [Abstract][Full Text] [Related]
11. A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.
Samardzija C; Luwor RB; Volchek M; Quinn MA; Findlay JK; Ahmed N
Mol Cancer; 2015 Aug; 14():152. PubMed ID: 26260289
[TBL] [Abstract][Full Text] [Related]
12. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
[TBL] [Abstract][Full Text] [Related]
13. A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.
Hoffmann RM; Crescioli S; Mele S; Sachouli E; Cheung A; Chui CK; Andriollo P; Jackson PJM; Lacy KE; Spicer JF; Thurston DE; Karagiannis SN
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331483
[TBL] [Abstract][Full Text] [Related]
14. Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
Yang J; Price MA; Wanshura LEC; He J; Yi M; Welch DR; Li G; Conner S; Sachs J; Turley EA; McCarthy JB
Melanoma Res; 2019 Aug; 29(4):365-375. PubMed ID: 31140988
[TBL] [Abstract][Full Text] [Related]
15. miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer.
Yu X; Zhang X; Wang G; Wang B; Ding Y; Zhao J; Liu H; Cui S
Cancer Cell Int; 2020 Nov; 20(1):534. PubMed ID: 33292230
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.
Liao J; Qian F; Tchabo N; Mhawech-Fauceglia P; Beck A; Qian Z; Wang X; Huss WJ; Lele SB; Morrison CD; Odunsi K
PLoS One; 2014; 9(1):e84941. PubMed ID: 24409314
[TBL] [Abstract][Full Text] [Related]
17. A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model.
Uranowska K; Samadaei M; Kalic T; Pinter M; Breiteneder H; Hafner C
Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34318902
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1.
Jin M; Yang Z; Ye W; Xu H; Hua X
PLoS One; 2014; 9(8):e103965. PubMed ID: 25090005
[TBL] [Abstract][Full Text] [Related]
20. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]